Table 3. Treatment factors and cardiotoxicity.

Variable	cAC group		Control group		Univariate Association
	Median [IQR]	%	Median [IQR]	%	OR1 (95%CI)	P value
Cumulative epirubicin /BSA ≥450mg/m2		60.6%		41.1%	2.21 (1.01–4.82)	0.047
Cumulative epirubicin dose / BSA (mg/m2)	450 [360–450]		400 [300–450]		1.12 (0.72–1.75)	0.61
Number anthracycline cycles	6 [4–6]		4 [4–6]		1.36 (1.01–1.84)	0.03
Radiotherapy		78.1%		88.4%	0.47 (0.17–1.27)	0.14
Left-sided radiotherapy		38.2%		44.2%	0.78 (0.36–1.70)	0.53
Trastuzumab		26.5%		16.8%	1.78 (0.73–4.34)	0.20
Aromatase inhibitor		14.7%		13.0%	1.08 (0.63–1.84)	0.79
Tamoxifen		41.2%		55.0%	0.57(0.27–1.23)	0.15
Interval from final anthracycline cycle to follow-up (months)	20.7 [17.3–27.3]		18.3 [14.9–22.1]		1.05 (1.00–1.09)	0.04
Interval from final anthracycline cycle–Trastuzumab untreated subjects only (months)	18.1 [17.1–27.0]		17.1 [14.6–20.9]		1.06 (1.00–1.12)	0.04

¹OR for a 100mg/m² dose increase and 1 month longer follow-up.